Literature DB >> 23313206

The CASP8 -652 6N insertion/deletion promoter polymorphism is associated with renal cell carcinoma risk and metastasis.

Michela de Martino1, Andrea Haitel, Georg Schatzl, Hans Christoph Klingler, Tobias Klatte.   

Abstract

PURPOSE: Caspase-8 is a key regulator of apoptosis. Its cancer cell antigen induced cell death activity is strongly impacted by the insertion/deletion promoter polymorphism CASP8 -652 6N ins/del (rs3834129). We studied the association of this polymorphism with renal cell carcinoma risk and pathology.
MATERIALS AND METHODS: In this hospital based case-control study 500 Austrian patients were genotyped, including 250 with renal cell carcinoma, and 250 age and gender matched healthy controls. Polymerase chain reaction amplified genomic DNA was evaluated by restriction fragment length polymorphism analysis and automatic sequencing. We assessed associations with renal cell carcinoma risk and pathological factors, and performed a meta-analysis of the literature.
RESULTS: The CASP8 -652 6N ins/del polymorphism was significantly linked to renal cell carcinoma (chi-square for trend = 9.50, p = 0.002). Compared with ins/ins, del/del was associated with a 57% decreased risk of the disease (OR 0.43, 95% CI 0.26-0.73, p = 0.002). Furthermore, del/del was associated with a lower risk of distant metastases (p <0.05) but not with T stage, N stage or grade. On meta-analysis the CASP8 -652 6N ins/del polymorphism was associated with renal cell carcinoma risk (p <0.001).
CONCLUSIONS: The del/del genotype of the CASP8 -652 6N ins/del promoter polymorphism decreases the overall risk of renal cell carcinoma. It may be associated with a decreased risk of metastasis. Larger studies are warranted to validate our findings.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  6 nucleotides; 6N; BMI; CASP8; PCR; RCC; Sp1; body mass index; carcinoma, renal cell; caspase 8; caspase-8; del; deletion; ins; insertion; kidney; polymerase chain reaction; polymorphism, single nucleotide; renal cell carcinoma; risk; stimulatory protein 1

Mesh:

Substances:

Year:  2013        PMID: 23313206     DOI: 10.1016/j.juro.2013.01.008

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

1.  Variants of SCARB1 and VDR Involved in Complex Genetic Interactions May Be Implicated in the Genetic Susceptibility to Clear Cell Renal Cell Carcinoma.

Authors:  Ewelina Pośpiech; Janusz Ligęza; Wacław Wilk; Aniela Gołas; Janusz Jaszczyński; Andrzej Stelmach; Janusz Ryś; Aleksandra Blecharczyk; Anna Wojas-Pelc; Jolanta Jura; Wojciech Branicki
Journal:  Biomed Res Int       Date:  2015-04-06       Impact factor: 3.411

2.  CASP8 -652 6N insertion/deletion polymorphism and overall cancer risk: evidence from 49 studies.

Authors:  Jiarong Cai; Qingjian Ye; Suling Luo; Ze Zhuang; Kui He; Zhen-Jian Zhuo; Xiaochun Wan; Juan Cheng
Journal:  Oncotarget       Date:  2017-05-25

3.  Analysis of 12 variants in the development of gastric and colorectal cancers.

Authors:  Giovanna C Cavalcante; Marcos At Amador; André M Ribeiro Dos Santos; Darlen C Carvalho; Roberta B Andrade; Esdras Eb Pereira; Marianne R Fernandes; Danielle F Costa; Ney Pc Santos; Paulo P Assumpção; Ândrea Ribeiro Dos Santos; Sidney Santos
Journal:  World J Gastroenterol       Date:  2017-12-28       Impact factor: 5.742

4.  CD146 Promoter Polymorphism (rs3923594) Is Associated with Recurrence of Clear Cell Renal Cell Carcinoma in Chinese Population.

Authors:  Gang Feng; Hou-Bao Huang; Xiao-Bing Ye; Peng Zhang; Jian-Jun Huang; Li-Zhu Huang; Long Cheng; Chun Pu; Guorong Li
Journal:  Dis Markers       Date:  2017-05-24       Impact factor: 3.434

5.  A meta-analysis of caspase-8 -652 6N del polymorphism and digestive tract cancer risk.

Authors:  Haina Du; Guo-Xin Song; Ming-Zhi Fang; Yong-Qian Shu; Xin Zhao; Ling-Jun Zhu
Journal:  J Biomed Res       Date:  2019-06-04

6.  The Relationship of Pyroptosis-Related Genes, Patient Outcomes, and Tumor-Infiltrating Cells in Bladder Urothelial Carcinoma (BLCA).

Authors:  Ruiyan Xie; Ming Xie; Litong Zhu; Joanne W Y Chiu; Wayne Lam; Desmond Y H Yap
Journal:  Front Pharmacol       Date:  2022-07-19       Impact factor: 5.988

7.  Identification of a secondary promoter of CASP8 and its related transcription factor PURα.

Authors:  Zhengwei Lin; Zhimin Guo; Yang Xu; Xiaohang Zhao
Journal:  Int J Oncol       Date:  2014-05-09       Impact factor: 5.650

8.  MicroRNA related polymorphisms and breast cancer risk.

Authors:  Sofia Khan; Dario Greco; Kyriaki Michailidou; Roger L Milne; Taru A Muranen; Tuomas Heikkinen; Kirsimari Aaltonen; Joe Dennis; Manjeet K Bolla; Jianjun Liu; Per Hall; Astrid Irwanto; Keith Humphreys; Jingmei Li; Kamila Czene; Jenny Chang-Claude; Rebecca Hein; Anja Rudolph; Petra Seibold; Dieter Flesch-Janys; Olivia Fletcher; Julian Peto; Isabel dos Santos Silva; Nichola Johnson; Lorna Gibson; Zoe Aitken; John L Hopper; Helen Tsimiklis; Minh Bui; Enes Makalic; Daniel F Schmidt; Melissa C Southey; Carmel Apicella; Jennifer Stone; Quinten Waisfisz; Hanne Meijers-Heijboer; Muriel A Adank; Rob B van der Luijt; Alfons Meindl; Rita K Schmutzler; Bertram Müller-Myhsok; Peter Lichtner; Clare Turnbull; Nazneen Rahman; Stephen J Chanock; David J Hunter; Angela Cox; Simon S Cross; Malcolm W R Reed; Marjanka K Schmidt; Annegien Broeks; Laura J Van't Veer; Frans B Hogervorst; Peter A Fasching; Michael G Schrauder; Arif B Ekici; Matthias W Beckmann; Stig E Bojesen; Børge G Nordestgaard; Sune F Nielsen; Henrik Flyger; Javier Benitez; Pilar M Zamora; Jose I A Perez; Christopher A Haiman; Brian E Henderson; Fredrick Schumacher; Loic Le Marchand; Paul D P Pharoah; Alison M Dunning; Mitul Shah; Robert Luben; Judith Brown; Fergus J Couch; Xianshu Wang; Celine Vachon; Janet E Olson; Diether Lambrechts; Matthieu Moisse; Robert Paridaens; Marie-Rose Christiaens; Pascal Guénel; Thérèse Truong; Pierre Laurent-Puig; Claire Mulot; Frederick Marme; Barbara Burwinkel; Andreas Schneeweiss; Christof Sohn; Elinor J Sawyer; Ian Tomlinson; Michael J Kerin; Nicola Miller; Irene L Andrulis; Julia A Knight; Sandrine Tchatchou; Anna Marie Mulligan; Thilo Dörk; Natalia V Bogdanova; Natalia N Antonenkova; Hoda Anton-Culver; Hatef Darabi; Mikael Eriksson; Montserrat Garcia-Closas; Jonine Figueroa; Jolanta Lissowska; Louise Brinton; Peter Devilee; Robert A E M Tollenaar; Caroline Seynaeve; Christi J van Asperen; Vessela N Kristensen; Susan Slager; Amanda E Toland; Christine B Ambrosone; Drakoulis Yannoukakos; Annika Lindblom; Sara Margolin; Paolo Radice; Paolo Peterlongo; Monica Barile; Paolo Mariani; Maartje J Hooning; John W M Martens; J Margriet Collée; Agnes Jager; Anna Jakubowska; Jan Lubinski; Katarzyna Jaworska-Bieniek; Katarzyna Durda; Graham G Giles; Catriona McLean; Hiltrud Brauch; Thomas Brüning; Yon-Dschun Ko; Hermann Brenner; Aida Karina Dieffenbach; Volker Arndt; Christa Stegmaier; Anthony Swerdlow; Alan Ashworth; Nick Orr; Michael Jones; Jacques Simard; Mark S Goldberg; France Labrèche; Martine Dumont; Robert Winqvist; Katri Pylkäs; Arja Jukkola-Vuorinen; Mervi Grip; Vesa Kataja; Veli-Matti Kosma; Jaana M Hartikainen; Arto Mannermaa; Ute Hamann; Georgia Chenevix-Trench; Carl Blomqvist; Kristiina Aittomäki; Douglas F Easton; Heli Nevanlinna
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

Review 9.  The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations.

Authors:  Sven Diederichs; Lorenz Bartsch; Julia C Berkmann; Karin Fröse; Jana Heitmann; Caroline Hoppe; Deetje Iggena; Danny Jazmati; Philipp Karschnia; Miriam Linsenmeier; Thomas Maulhardt; Lino Möhrmann; Johannes Morstein; Stella V Paffenholz; Paula Röpenack; Timo Rückert; Ludger Sandig; Maximilian Schell; Anna Steinmann; Gjendine Voss; Jacqueline Wasmuth; Maria E Weinberger; Ramona Wullenkord
Journal:  EMBO Mol Med       Date:  2016-05-02       Impact factor: 12.137

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.